“And we really see these two products even before the combination that Roopal spoke about as having a long runway of at least for at least the next eight years and we feel very good about that from that perspective.”

In context

“s any potential for pretreatment segmentation in the future consistent with what we do in oncology. Thus far no real successes, would say maybe there's hints in TL1A. But we're going to generate that data as well to see if there's opportunities to be able to use biomarkers in the future to segment these patients. Scott Reents: I might add, when we look at Skyrizi and Rinvoq, certainly we're very pleased with the strong demand in the quarter and that led to us taking a combined $900 million of increased guidance for the year. We've also given the long term guidance in 2027, which we continue to feel very confident in. And also I think it's worthwhile to think about Rinvoq will have a second wave of indications towards the end of the decade. It will add a couple of billion dollars of sales. And we really see these two products even before the combination that Roopal spoke about as having a long runway of at least for at least the next eight years and we feel very good about that from that perspective. Rob Michael: And this is Rob. I'll just to add on to that. I think from strategically, when we look at the company and we have this clear runway to growth for at least the next eight years, we can use that time and obviously we're looking to elevate the standard of care for immunology patients. We think these combination studies are a way to accomplish that. But we're going to use that time to and just as we did with Humira, we came up with Skyrizi and Rinvoq as a way to elevate the standard of care And that really launched into a second chapter of the company. Third chapter is going to be as you think about the growth beyond Skyrizi and Rinvoq. And we have the time and we're investing appropriately to identify what those drivers will be and within immunology and outside of it. I mean we”